AU2022316237A1 - Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof - Google Patents

Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof Download PDF

Info

Publication number
AU2022316237A1
AU2022316237A1 AU2022316237A AU2022316237A AU2022316237A1 AU 2022316237 A1 AU2022316237 A1 AU 2022316237A1 AU 2022316237 A AU2022316237 A AU 2022316237A AU 2022316237 A AU2022316237 A AU 2022316237A AU 2022316237 A1 AU2022316237 A1 AU 2022316237A1
Authority
AU
Australia
Prior art keywords
peptide
group
amino acid
condition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022316237A
Other languages
English (en)
Inventor
Andrew GEARING
David KENLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lateral IP Pty Ltd
Original Assignee
Lateral IP Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021902267A external-priority patent/AU2021902267A0/en
Application filed by Lateral IP Pty Ltd filed Critical Lateral IP Pty Ltd
Publication of AU2022316237A1 publication Critical patent/AU2022316237A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
AU2022316237A 2021-07-23 2022-07-22 Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof Pending AU2022316237A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021902267A AU2021902267A0 (en) 2021-07-23 Compositions and uses thereof
AU2021902267 2021-07-23
PCT/AU2022/050778 WO2023000038A1 (en) 2021-07-23 2022-07-22 Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof

Publications (1)

Publication Number Publication Date
AU2022316237A1 true AU2022316237A1 (en) 2024-02-01

Family

ID=84980448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022316237A Pending AU2022316237A1 (en) 2021-07-23 2022-07-22 Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof

Country Status (8)

Country Link
US (1) US20250263435A1 (cg-RX-API-DMAC10.html)
EP (1) EP4373509A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024525959A (cg-RX-API-DMAC10.html)
KR (1) KR20240036634A (cg-RX-API-DMAC10.html)
CN (1) CN117813105A (cg-RX-API-DMAC10.html)
AU (1) AU2022316237A1 (cg-RX-API-DMAC10.html)
CA (1) CA3226259A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023000038A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7751583B2 (ja) * 2019-12-27 2025-10-08 ラテラル、アイピー、プロプライエタリー、リミテッド 環状ペプチド受容体ランチオニンシンテターゼc様タンパク質(lancl)及びその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
AUPQ981700A0 (en) * 2000-09-01 2000-09-28 Metabolic Pharmaceuticals Limited Product and method for control of obesity
WO2007068039A1 (en) * 2005-12-12 2007-06-21 Metabolic Pharmaceuticals Limited Treatment of weight gain in estrogen deficient mammals
WO2009013621A2 (en) * 2007-05-30 2009-01-29 Auckland Uniservices Limited Inhibitors for growth hormone and related hormones, and methods of use thereof
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CA3032944A1 (en) * 2016-08-05 2018-02-08 Sera Prognostics, Inc. Biomarkers for predicting preterm birth in a pregnant female exposed to progestogens
CN110546157A (zh) * 2017-02-22 2019-12-06 健康之语公司 筛查感染的方法
WO2019136528A1 (en) * 2018-01-15 2019-07-18 Lateral IP Pty Ltd Peptides and uses thereof
WO2019183686A1 (en) * 2018-03-29 2019-10-03 Lateral IP Pty Ltd Cyclic peptides and uses thereof
US11149256B2 (en) * 2018-09-26 2021-10-19 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
EP3671210A1 (en) * 2018-12-21 2020-06-24 Biosystems International KFT Lung cancer protein epitomic biomarkers
JP7751583B2 (ja) * 2019-12-27 2025-10-08 ラテラル、アイピー、プロプライエタリー、リミテッド 環状ペプチド受容体ランチオニンシンテターゼc様タンパク質(lancl)及びその使用
RU2731919C1 (ru) * 2020-03-25 2020-09-09 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в плаценте пептидом, имитирующим альфа-спираль B эритропоэтина, при ADMA-подобной модели преэклампсии
RU2751964C1 (ru) * 2021-02-17 2021-07-21 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ снижения агрегационной способности тромбоцитов

Also Published As

Publication number Publication date
CN117813105A (zh) 2024-04-02
US20250263435A1 (en) 2025-08-21
WO2023000038A1 (en) 2023-01-26
JP2024525959A (ja) 2024-07-12
KR20240036634A (ko) 2024-03-20
EP4373509A4 (en) 2025-10-29
CA3226259A1 (en) 2023-01-26
EP4373509A1 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
US10888605B2 (en) GLP-1 compositions and uses thereof
US11752190B2 (en) Modulators of complement activity
US10688096B2 (en) Methods for treatment of sleep-related breathing disorders
US20110053859A1 (en) Methods to reduce the effects of sleep deprivation
US11123399B2 (en) Modulators of complement activity
CA2817787C (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
RS65144B1 (sr) Postupak za lečenje prader-vilijevog sindroma
US20250263435A1 (en) Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof
Collins et al. Trofinetide. Glycine-proline-glutamate (GPE) analogue, treatment of Rett syndrome, treatment of fragile X syndrome
US12492223B2 (en) Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof
CN108135880A (zh) 用于治疗神经退化性疾病的方法及组成物
US20230256059A1 (en) Compositions for treating respiratory tract infection and uses thereof
EP4346867A1 (en) Compositions for treating inflammatory airway disease and uses thereof
CA3047320A1 (en) Methods of administering hepcidin
WO2025037259A1 (en) Methods and compositions for preventing or treating severe asthma
HK40031446B (en) Modulators of complement activity
HK40031446A (en) Modulators of complement activity
Class et al. Patent application title: METHODS TO REDUCE THE EFFECTS OF SLEEP DEPRIVATION Inventors: Samuel A. Deadwyler (Lewisville, NC, US) Robert E. Hampson (Kernersville, NC, US) Linda Porrino (Lewisville, NC, US) Michael Todd (Winston Salem, NC, US) Thomas N. Thannickal (Winnetka, CA, US) Yuan-Yan Lai (North Hills, CA, US) Jerome M. Siegel (Northridge, CA, US) Assignees: The US Government Respresented by the Department of Veterans Affairs